Prognostic Biomarkers for Melanoma Immunotherapy

被引：11
|
作者：
Twitty, Christopher G. [1 ]
Huppert, Laura A. [2 ]
Daud, Adil I. [2 ]
机构：
[1] OncoSec Inc, 3565 Gen Atom Ct, San Diego, CA 92121 USA
[2] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, 1600 Divisadero St,Rm A741, San Francisco, CA 94143 USA
来源：
CURRENT ONCOLOGY REPORTS | 2020年 / 22卷 / 03期
关键词：
Immune checkpoint inhibitors; Programmed death-1 (PD-1); Programmed death ligand-1 (PD-L1); Exhausted T cells (Tex); Tumor microenvironment (TME); Memory T cells (Tmem); Tumor mutation burden; Circulating tumor DNA; TUMOR-INFILTRATING LYMPHOCYTES; LIGAND; EXPRESSION; PD-1; BLOCKADE; MUTATIONAL LANDSCAPE; COMBINED NIVOLUMAB; PREDICTS RESPONSE; UVEAL MELANOMA; B7; FAMILY; T-CELLS; CANCER;
D O I：
10.1007/s11912-020-0886-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of Review Recent developments in immunotherapy have transformed the landscape of melanoma therapy. Here, we review markers for response to immunotherapy. Recent Findings Current immunotherapies disable immune checkpoints on T cells and other immune cells and allow immune rejection of tumor. This process depends crucially on a preexisting response to the development of the melanoma. Here we describe the complexity of the anti-tumor immune response and the links to the development of markers that are currently used or under investigation in the clinic. We describe immune response biomarkers along with new developments that could translate into advances.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Prognostic Biomarkers for Melanoma Immunotherapy
    Christopher G. Twitty
    Laura A. Huppert
    Adil I. Daud
    [J]. Current Oncology Reports, 2020, 22
  • [2] Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
    Nyakas, M.
    Aamdal, E.
    Jacobsen, K. D.
    Guren, T. K.
    Aamdal, S.
    Hagene, K. T.
    Brunsvig, P.
    Yndestad, A.
    Halvorsen, B.
    Tasken, K. A.
    Aukrust, P.
    Maelandsmo, G. M.
    Ueland, T.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2019, 197 (01): : 74 - 82
  • [3] Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma
    Chmielowski, B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (01) : 20 - 20
  • [4] Prognostic biomarkers of cutaneous melanoma
    Ding, Liang
    Gosh, Alexandra
    Lee, Delphine J.
    Emri, Gabriella
    Huss, Wendy J.
    Bogner, Paul N.
    Paragh, Gyorgy
    [J]. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2022, 38 (05) : 418 - 434
  • [5] Prognostic and predictive biomarkers in melanoma
    Maher, Nigel G.
    Vergara, Ismael A.
    Long, Georgina V.
    Scolyer, Richard A.
    [J]. PATHOLOGY, 2024, 56 (02) : 259 - 273
  • [6] Biomarkers predictive of response to immunotherapy in melanoma
    Pourmir, Ivan
    Gey, Alain
    Pineau, Josephine
    Lebbe, Celeste
    Tartour, Eric
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2023, 207 (06): : 769 - 778
  • [7] Emerging biomarkers for cancer immunotherapy in melanoma
    Axelrod, Margaret L.
    Johnson, Douglas B.
    Balko, Justin M.
    [J]. SEMINARS IN CANCER BIOLOGY, 2018, 52 : 207 - 215
  • [8] Prognostic and predictive biomarkers in melanoma: an update
    Foth, Mona
    Wouters, Jasper
    de Chaumont, Ciaran
    Dynoodt, Peter
    Gallagher, William M.
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 223 - 237
  • [9] Prognostic biomarkers for survival in mucosal melanoma
    Thierauf, Julia C.
    Kaluziak, Stefan T.
    Codd, Elizabeth
    Dybel, Stacy N.
    Jobbagy, Soma
    Purohit, Rashi
    Farahani, Alex A.
    Dedeilia, Aikaterini
    Naranbhai, Vivek
    Hoang, Mai P.
    Fisch, Adam S.
    Ritterhouse, Lauren
    Boland, Genevieve M.
    Lennerz, Jochen K.
    Iafrate, A. John
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2023, 36 (05) : 378 - 387
  • [10] microRNAs as Prognostic Biomarkers in Malignant Melanoma
    Daoud, M. S. Abi
    Nuin, P.
    Chen, J.
    Zhang, X.
    Feilloter, H.
    Tron, V. A.
    [J]. MODERN PATHOLOGY, 2012, 25 : 113A - 113A
12345